Hematologic Malignancy
T-Cell Large Granular Lymphocyte Leukemia
CI-CAN-00004059LGLLExplore in graph →
Hematologic8 active trials1 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004059LGLLExplore in graph →
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05010005 | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | recruiting | Phase 1 | 70 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05978141 | A Registry for People With T-cell Lymphoma | recruiting | — | 1,000 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04645199 |
| National Longitudinal Cohort of Hematological Diseases(NICHE) |
| recruiting |
| — |
| 2,300 |
| Institute of Hematology & Blood Diseases Hospital, ChinaOTHER |
| 1 |
| Feb 12, 2026 |
| clinicaltrials |
| NCT05592015 | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 30 | Jonathan BrammerOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02863692 | Registry of the German CLL Study Group(CLL-Registry) | recruiting | — | 8,000 | German CLL Study GroupOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06530576 | Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06716658 | JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 48 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06530550 | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 51 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07019766 | National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia(NICHE-LGLL) | recruiting | — | 9,999 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 17, 2025 | clinicaltrials |
Data updated 21 days agoSource updated Sep 9, 2026source: clinicaltrials